Interaction studies of E. coli uracil phosphoribosyltransferase with 5-fluorouracil for potent anti cancer activity

Taylor-made production of pyrimidine nucleoside-5'-monophosphate analogues by highly stabilized mutant uracil phosphoribosyltransferase from Toxoplasma gondii

Nowadays, enzymatic synthesis of nucleotides is an efficient and sustainable alternative to chemical methodologies. In this regard, after the biochemical characterization of wild-type and mutant uracil phosphoribosyltransferases from Toxoplasma gondii (TgUPRT, TgUPRT_2, and TgUPRT₃), TgUPRT₂ was selected as the optimal candidate (69.5 IU mg^-1, UMP synthesis) for structure-guided immobilization onto Ni²⁺ chelate (M_NiUPRT₂) and onto glutaraldehyde-activated microparticles (M_GlUPRT₂). Among resulting derivatives, M_NiUPRT₂3 (6127 IU g^-1_biocat; 92% retained activity; 3-5 fold enhanced stability at 50-60 °C) and M_GlUPRT₂N (3711 IU g^-1_biocat; 27% retained activity; 8-20 fold enhanced stability at 50-60 °C) displayed the best operability. Moreover, the enzymatic synthesis of different pyrimidine NMPs was performed. Finally, the reusability of both derivatives in 5-FUMP synthesis (M_NiUPRT₂3, 80% retained activity after 7 cycles, 5 min; M_GlUPRT₂N, 70% retained activity after 10 cycles, 20 min) was carried out at short times.

Emerging implications of nonmammalian cytosine deaminases on cancer therapeutics

Nonmammalian cytosine deaminases (CDs) have been investigated for last 30 years in the context of cancer therapy. The therapeutic effect of CD is based on its ability to catalyze the conversion of nontoxic prodrug 5-fluorocytosine (5FC) into the anticancer drug 5-fluorouracil (5FU) by deamination of the number 4 carbon of 5FC. This deamination property of CD has been explored to develop innovative therapeutic approach for treatment of cancer. A general overview is needed for the identification of efficient cytosine deaminases for potential use in cancer therapy. In this review, we have discussed about nonmammalian CDs for a variety of prodrug gene/enzyme therapy applications with several recent examples. Finally, we have provided a prospective on the future aspects of CDs and their applications in cancer therapy.